Skip to main content


We're creating a new version of this page. See preview

Volume 3 Supplement 1


  • Poster presentation
  • Open Access

Hydrocortisone in treatment of severe sepsis and septic shock with acute respiratory distress syndrome: a randomised controlled trial

  • 1,
  • 1,
  • 1, 2 and
  • 1
Intensive Care Medicine Experimental20153 (Suppl 1) :A808

  • Published:


  • Hydrocortisone
  • Septic Shock
  • Hyperglycemia
  • Lung Injury
  • Severe Sepsis


Severe sepsis and septic shock are serious conditions associated with high mortality, especially in the patients complicated with acute respiratory distress syndrome (ARDS). Corticosteroids are recommended in patients who do not respond to fluid resuscitation and vasopressors. However, efficacy of this treatment in severe sepsis patients with ARDS has not been investigated.


To examine efficacy of moderate dose of hydrocortisone in the treatment of severe sepsis/septic shock complicated with ARDS.


A single center, placebo-controlled, randomized, double blind study which included adult patients with severe sepsis or septic shock and ARDS, onset within 24 hours. They were randomly assigned into two groups. The “study group” received hydrocortisone 50 mg intravenous every 6 hours for 7 days, while the “controlled group” received normal saline in the comparable volume. The primary outcome was 28 days mortality.


A total of 197 patients were included. Ninety eight were in “study group” and 99 were in the “control group”. While baseline characteristics were similar, the study group had longer organ support-free days in the 28 days (13.9+10.3 vs 10.8+10.1, P = 0.04), shorter vasopressor-dependent days (3.8+3.3 vs 5.2+5.7, P = 0.04), lower lung injury score at the 3rd day after treatment (1.5+0.8 vs 1.8+1.0, P = 0.03) and improve PaO2/FiO2 ratio at the 3rd day after treatment (273.9+126.9 vs 227.6+110.3, P = 0.007). The incidence of hyperglycemia was also higher in the study group. Mortality in the study group was lower although statistical difference was not reached (25.5% vs 31.3%, P = 0.37).


Hydrocortisone improved outcomes; namely organ support-free days, vasopressor-dependent days and oxygenation, in severe sepsis or septic shock patients with ARDS. There was a trend toward mortality reduction in the study group but the statistical significant was not reached. ( number, NCT01284452)

Grant Acknowledgment

Facualty of Medicine, Siriraj Hospital, Mahidol University.

Authors’ Affiliations

Siriraj Hospital, Mahidol University, Critical Care Medicine, Bangkok, Thailand
Prince of Songkla University, Songkla, Thailand


  1. Brower RB, Pronovost JE, Sevransky JS, Martin G, Mendez-Tellez PC: Mortality in sepsis versus non-sepsis induced acute lung injury. Crit Care. 2009, 13: 1-6.Google Scholar
  2. Tang BMC, Craig J, Eslick GD: Use of corticosteroids in acute lung injury and ARDS; A systematic reviews and meta-analysis. Crit Care Med. 2009, 37: 1594-1602. 10.1097/CCM.0b013e31819fb507.PubMedView ArticleGoogle Scholar


© Tongyoo et al.; 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.